Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Reconstitution of HuR-Inhibited CUGBP1 Expression Protects Cardiomyocytes from Acute Myocardial Infarction-Induced Injury.

Gu L, Wang H, Wang J, Guo Y, Tang Y, Mao Y, Chen L, Lou H, Ji G.

Antioxid Redox Signal. 2017 Nov 10;27(14):1013-1026. doi: 10.1089/ars.2016.6880. Epub 2017 Mar 28.

PMID:
28350193
2.

Green Tea Polyphenol Induces Changes in Cancer-Related Factors in an Animal Model of Bladder Cancer.

Matsuo T, Miyata Y, Asai A, Sagara Y, Furusato B, Fukuoka J, Sakai H.

PLoS One. 2017 Jan 31;12(1):e0171091. doi: 10.1371/journal.pone.0171091. eCollection 2017.

3.

Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas.

Dufies M, Giuliano S, Ambrosetti D, Claren A, Ndiaye PD, Mastri M, Moghrabi W, Cooley LS, Ettaiche M, Chamorey E, Parola J, Vial V, Lupu-Plesu M, Bernhard JC, Ravaud A, Borchiellini D, Ferrero JM, Bikfalvi A, Ebos JM, Khabar KS, Grépin R, Pagès G.

Cancer Res. 2017 Mar 1;77(5):1212-1226. doi: 10.1158/0008-5472.CAN-16-3088. Epub 2017 Jan 13.

4.

Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis.

Blanco FF, Preet R, Aguado A, Vishwakarma V, Stevens LE, Vyas A, Padhye S, Xu L, Weir SJ, Anant S, Meisner-Kober N, Brody JR, Dixon DA.

Oncotarget. 2016 Nov 8;7(45):74043-74058. doi: 10.18632/oncotarget.12189.

5.

Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat.

Amadio M, Pascale A, Cupri S, Pignatello R, Osera C, D Agata V, D Amico AG, Leggio GM, Ruozi B, Govoni S, Drago F, Bucolo C.

Pharmacol Res. 2016 Sep;111:713-720. doi: 10.1016/j.phrs.2016.07.042. Epub 2016 Jul 27.

PMID:
27475885
6.

MiR-31 Functions as a Tumor Suppressor in Lung Adenocarcinoma Mainly by Targeting HuR.

Xu H, Ma J, Zheng J, Wu J, Qu C, Sun F, Xu S.

Clin Lab. 2016;62(4):711-8.

7.

Human antigen R is positively associated with malignant aggressiveness via upregulation of cell proliferation, migration, and vascular endothelial growth factors and cyclooxygenase-2 in prostate cancer.

Mitsunari K, Miyata Y, Asai A, Matsuo T, Shida Y, Hakariya T, Sakai H.

Transl Res. 2016 Sep;175:116-28. doi: 10.1016/j.trsl.2016.04.002. Epub 2016 Apr 29.

8.

Induction of VEGFA mRNA translation by CoCl2 mediated by HuR.

Osera C, Martindale JL, Amadio M, Kim J, Yang X, Moad CA, Indig FE, Govoni S, Abdelmohsen K, Gorospe M, Pascale A.

RNA Biol. 2015;12(10):1121-30. doi: 10.1080/15476286.2015.1085276. Epub 2015 Sep 1.

9.

HIF-inducible miR-191 promotes migration in breast cancer through complex regulation of TGFβ-signaling in hypoxic microenvironment.

Nagpal N, Ahmad HM, Chameettachal S, Sundar D, Ghosh S, Kulshreshtha R.

Sci Rep. 2015 Apr 13;5:9650. doi: 10.1038/srep09650.

10.

Hu antigen R (HuR) is a positive regulator of the RNA-binding proteins TDP-43 and FUS/TLS: implications for amyotrophic lateral sclerosis.

Lu L, Zheng L, Si Y, Luo W, Dujardin G, Kwan T, Potochick NR, Thompson SR, Schneider DA, King PH.

J Biol Chem. 2014 Nov 14;289(46):31792-804. doi: 10.1074/jbc.M114.573246. Epub 2014 Sep 19.

11.

Chemokine-coupled β2 integrin-induced macrophage Rac2-Myosin IIA interaction regulates VEGF-A mRNA stability and arteriogenesis.

Morrison AR, Yarovinsky TO, Young BD, Moraes F, Ross TD, Ceneri N, Zhang J, Zhuang ZW, Sinusas AJ, Pardi R, Schwartz MA, Simons M, Bender JR.

J Exp Med. 2014 Sep 22;211(10):1957-68. doi: 10.1084/jem.20132130. Epub 2014 Sep 1.

12.

The PPARβ agonist L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanism.

Roche E, Lascombe I, Bittard H, Mougin C, Fauconnet S.

Cell Signal. 2014 Feb;26(2):433-43. doi: 10.1016/j.cellsig.2013.10.006. Epub 2013 Oct 28.

PMID:
24172859
13.

The interplay of HuR and miR-3134 in regulation of AU rich transcriptome.

Sharma S, Verma S, Vasudevan M, Samanta S, Thakur JK, Kulshreshtha R.

RNA Biol. 2013 Aug;10(8):1283-90. doi: 10.4161/rna.25482. Epub 2013 Jun 20.

14.

MPT0B098, a novel microtubule inhibitor that destabilizes the hypoxia-inducible factor-1α mRNA through decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR.

Cheng YC, Liou JP, Kuo CC, Lai WY, Shih KH, Chang CY, Pan WY, Tseng JT, Chang JY.

Mol Cancer Ther. 2013 Jul;12(7):1202-12. doi: 10.1158/1535-7163.MCT-12-0778. Epub 2013 Apr 25. Erratum in: Mol Cancer Ther. 2013 Sep;12(9):1919.

15.

Mutant tristetraprolin: a potent inhibitor of malignant glioma cell growth.

Suswam EA, Shacka JJ, Walker K, Lu L, Li X, Si Y, Zhang X, Zheng L, Nabors LB, Cao H, King PH.

J Neurooncol. 2013 Jun;113(2):195-205. doi: 10.1007/s11060-013-1112-8. Epub 2013 Mar 25.

16.

High expression of HuR in cytoplasm, but not nuclei, is associated with malignant aggressiveness and prognosis in bladder cancer.

Miyata Y, Watanabe S, Sagara Y, Mitsunari K, Matsuo T, Ohba K, Sakai H.

PLoS One. 2013;8(3):e59095. doi: 10.1371/journal.pone.0059095. Epub 2013 Mar 13.

17.

Antagonistic function of the RNA-binding protein HuR and miR-200b in post-transcriptional regulation of vascular endothelial growth factor-A expression and angiogenesis.

Chang SH, Lu YC, Li X, Hsieh WY, Xiong Y, Ghosh M, Evans T, Elemento O, Hla T.

J Biol Chem. 2013 Feb 15;288(7):4908-21. doi: 10.1074/jbc.M112.423871. Epub 2012 Dec 6.

18.
19.

Association of the von Hippel-Lindau protein with AUF1 and posttranscriptional regulation of VEGFA mRNA.

Xin H, Brown JA, Gong C, Fan H, Brewer G, Gnarra JR.

Mol Cancer Res. 2012 Jan;10(1):108-20. doi: 10.1158/1541-7786.MCR-11-0435. Epub 2011 Nov 15.

20.

HuR's role in gemcitabine efficacy: an exception or opportunity?

Brody JR, Gonye GE.

Wiley Interdiscip Rev RNA. 2011 May-Jun;2(3):435-44. doi: 10.1002/wrna.62. Epub 2010 Nov 30. Review.

PMID:
21957028

Supplemental Content

Loading ...
Support Center